Zhejiang Medicine Co. Ltd. (ZMC), a major China-listed active pharmaceutical ingredient (API) and intermediates supplier, has taken action in response to a warning letter sent by the US Food and Drug Administration to one of its subsidiaries for concealing API test data and other irregularities, the company has disclosed.
ZMC said Xinchang Pharmaceutical Factory, a subsidiary that violated FDA current good manufacturing practice (cGMP) for APIs, sent the US...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?